Domain Names E-CommerceLitigationIP Rights MaintenanceIP as PropertyNews & BulletinsTrademarksIntroductionBiotechnologyComputer Related InventionsUS and Foreign Patent PracticePatents
HomeAbout UsContact UsSearchQuick Search:
 
Patents / Biotechnology / US Biotechnology Practice
 

8.1 Direct Infringement


In order to be held as a direct infringer of a United States patent under 35 USC § 271(a), it is necessary during the life of the patent to have made, used, offered to sell [182] or sold what is claimed in the patent within the United States or to have imported the patented invention into the United States. Under this test one can be liable for patent infringement even though one was unaware of the patent or that the acts one is carrying out are tortious. [183] Furthermore it has long been the law that one does not have to sell the product one produces to be an infringer of a patent, mere manufacture, at least if for a commercial purpose will suffice. The possibility of suit against someone offering a product for sale was added to the statute as part of the Uruguay Round Amendments Act, taking effect on January 1, 1996. If the offer for sale originates from the United States there may be an infringement even if the physical embodiment never enters the United Sates as was the case in Halmar Robicon Group v. Texas Instruments [184] where a letter making an offer for sale originated in Texas but the goods in question were made in Japan and shipped direct to a customer in Canada. It appears that the term “offer for sale” in this context may have a broader meaning than is normal in contract law and may include acts that a contract lawyer would find to be merely an invitation to make an offer. [185] It seems clear, however, that an uncompleted offer to donate an alleged infringing article is not an infringement. [186]

Limited use of an invention for non-commercial experimental purposes may, however, be permissible without being an infringement. To succeed with such a defense, it is however, necessary that the use be of an entirely non-commercial nature. [187]


[182] 35 USC § 271(i) makes it clear that an offer for sale is only an infringement if the sale itself will occur before the expiration of the term of the patent.
[183] As stated by the Supreme Court in Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 181 USPQ 673 (1974), patent protection "goes not only to copying the subject matter, which is forbidden under the Copyright Act ... but also forbids independent creation."
[184] 53 USPQ2d 1501 (W.D. Penn. 1999).
[185] 3D Systems Inc. v. Aarotech Laboratories Inc., 160 F.3d 1373, 48 USPQ2d 1773 (Fed. Cir. 1998) where a price quotation letter was held to be an offer for sale for the purpose of determining patent infringement. The issue was considered further in Rotec Industries v. Mitsubishi Corp., 55 USPQ2d 1001 where it was held that there was no evidence to prove that an offer had been made so that the exact definition of what constituted an offer was not fully decided. The case did, however, make it clear that for there to be an infringing offer for sale, that which was offered had to be the whole invention as claimed and not merely a part of it.
[186] HollyAnne Corp. v. TFT Inc. , 53 USPQ2d 1201 (Fed. Cir. 1999).
[187] Roche Products Inc. v. Bolar Pharmaceutical Co., Inc., 221 USPQ 937 (Fed. Cir. 1984) held that the carrying out of experiments with a view to filing an application with the FDA for approval to market a patented drug did not fall within the experimental use exception, noting that the experiments were "solely for business reasons and not for amusement, to satisfy idle curiosity or for strictly philosophical inquiry". This decision led to the enactment of 35 USC § 271(e) as part of the Drug Price Competition and Patent Term Restoration Act of 1984. This is discussed below.


Previous Next Contents
Contact Us


[Home] [About Ladas & Parry LLP] [Contact Us] [Search]
[Trademarks] [Domain Names & E-Commerce] [Patents & Copyrights]
[Litigation] [IP Rights Maintenance] [IP as Property] [News & Bulletins]

© Copyright 2002 John Richards - Posted July 2002
Please read our disclaimer.